Clinical Use of Factor IX Concentrates

• References

• 1 Biggs R. 1975; Editorial: The clinical use of factor IX concentrates. Thrombosis et Diathesis Haemor-rhagica 53: 403
• 2 Dike G. W. R, Bidwell E, and Rizza C. R. 1972; The preparation and clinical use of a new concentrate containing factor IX, prothrombin and factor X and of a separate concentrate of factor VII. British Journal of Haematology 22: 469.
• 3 Engel G. 1972; Addition of drugs to intravenous fluids. Drug Intelligence and Clinical Pharmacy 6: 145.
• 4 Gazzard B. G, Lewis M. L, Ash G, Rizza C. R, Bidwell E, and Williams R. 1974; Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure. Journal of the British Society of Gastroenterology 15: 993.
• 5 Hampson W. C. J, Harris F. C, Lucas H. K, Roberts P. H, Mc Call I. W, Jackson P. C, Powell N. L, and Staddon G. E. 1974; Failure of low-dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. Lancet II: 795.
• 6 Kasper C. K. 1975; Thromboembolic complications. Thrombosis et Diathesis Haemorrhagica 33: 640
• 7 Lane J. L, Rizza C. R, and Snape T. J. 1975; A five year experience of the use of factor-IX type DE(1) concentrate for the treatment of Christmas disease at Oxford. British Journal of Haematology 30: 431.
• 8 Ménaché D, and Roberts H. R. 1975; Summary Report and Recommendations of the Task Force Members and Consultants. Thrombosis et Diathesis Haemorrhagica 33: 645.
• 9 Morris G. K, Henry A. P. J, and Preston B. J. 1974; Prevention of deep-vein thrombosis by low-dose heparin in patients undergoing total hip replacement. Lancet II: 797.